Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.

EuroBioForum 2013 - Day 1 | Wolfgang Eberle

683 views

Published on

EuroBioForum 2013 2nd Annual Conference
27-28 May 2013 - Hilton Munich City, Munich, Germany
http://www.eurobioforum.eu/2013

=======================================

# NATIONAL PERSPECTIVES #

Belgium
Working across disciplines for our health benefit - From successful strategies for biotech and nanotech to Nanotech for Health in Flanders

Wolfgang Eberle
Funded Program Manager Life Science Technologies Imec

=======================================

http://www.eurobioforum.eu

Published in: Health & Medicine, Technology
  • Be the first to comment

  • Be the first to like this

EuroBioForum 2013 - Day 1 | Wolfgang Eberle

  1. 1. 27-­‐28  May  2013,  Munich,  Germany    EuroBioForum  2013  2nd  Annual  Conference  Wolfgang  Eberle  imec  
  2. 2. Solu>ons  in  a  sea  of  technologies  …  a  solu>on?  
  3. 3. IP  …  R&D  effort  …  cost  …  quality  control  …  risk  management  …  tes>ng  …  approval  …  system  architecture  …  return-­‐of-­‐investment  …  lifecycle  …  >me-­‐to-­‐market  …  robustness  …  purpose  …  market?  
  4. 4. •  develop  suitable  technologies  to  manage    –  disease  complexity  –  treatment  complexity  –  cost  efficiency  •  ways  to  involve  all  stakeholders  –  mul>ply  excellence  by  interac>on  between  different  clusters  –  Increase  the  chance  to  bring  R&D  innova>on  to  each  of  us  –  incen>ves  to  keep  R&D  innova>on  ongoing  •  methods  &  policies  suppor>ng  longer  term  strategies  –  new  structured  alliances  –  gap  funding  WHAT  ARE  WE  LOOKING  FOR?  
  5. 5. FLANDERS: Key Figures and competenciespop : 6 3 million ( 58 % f BE)pop.: 6.3 million (= 58 % of BE)GDP: €202.6 billion (2010)GDP / capita: €32,300 (2010)companies: 462,661 (2011)R&D personnel: 38,216 FTE (2010)% GERD / BBP: 2 15% (2011)% GERD / BBP: 2.15% (2011)Innovating companies : 53% of total (CIS)FP7: VL return: 2.43%; or € 539.1 million (Oct 2011)G € ( / f )GERD: €4.33 billion (2/3 of BE) (2010) , of which:€ 2.82 billion BERD;VLA public STI outlays: €1,891 million, (of which €1.20 billion R&D) ;p y ( )Fed. public R&D outlays: €238 million;EU STI funding: +- €120 m (€103 m FP7; €8 m ERDF ; €7 m Interreg);exclusive powers on higher education, scientific research, innovation(= all broad R&D & I (in)direct support, all research related to own regional &community competencies, universities, university colleges, access to finance,Flemish government | Department of Economy, Science and Innovation4y p , , y g , ,various knowledge institutes, PROs, scientific institutes, science parks).Flanders  |  Belgium  |  Europe  FLANDERS: Key Figures and competenciespop : 6 3 million ( 58 % f BE)pop.: 6.3 million (= 58 % of BE)GDP: €202.6 billion (2010)GDP / capita: €32,300 (2010)companies: 462,661 (2011)R&D personnel: 38,216 FTE (2010)% GERD / BBP: 2 15% (2011)% GERD / BBP: 2.15% (2011)Innovating companies : 53% of total (CIS)FP7: VL return: 2.43%; or € 539.1 million (Oct 2011)G € ( / f )GERD: €4.33 billion (2/3 of BE) (2010) , of which:€ 2.82 billion BERD;VLA public STI outlays: €1,891 million, (of which €1.20 billion R&D) ;p y ( )Fed. public R&D outlays: €238 million;EU STI funding: +- €120 m (€103 m FP7; €8 m ERDF ; €7 m Interreg);exclusive powers on higher education, scientific research, innovation(= all broad R&D & I (in)direct support, all research related to own regional &community competencies, universities, university colleges, access to finance,Flemish government | Department of Economy, Science and Innovation4y p , , y g , ,various knowledge institutes, PROs, scientific institutes, science parks).
  6. 6. Innova>on  framework  Neuro-electronics research -flanders (NERF)3K.U.Leuven &University HospitalVIBBiotechnologyimecNanoelectronics+ 1000 m2 NERF bio-lab @ imec~ 1950 researchers~ 260 PhDs~ 350 industrial residents~ 300 MEuro R&D~ 18000 researchers &staff (>2000 beds;doubling in the next years)~ 570 PhDs~ 330 MEuro R&D~ 1250 researchers~ 180 PhDs~ 90 MEuro R&D
  7. 7. Co-­‐locate  for  efficient  life  science  technology  R&D  
  8. 8. Neuro-electronics research -flanders (NERF)3K.U.Leuven &University HospitalVIBBiotechnologyimecNanoelectronics+ 1000 m2 NERF bio-lab @ imec~ 1950 researchers~ 260 PhDs~ 350 industrial residents~ 300 MEuro R&D~ 18000 researchers &staff (>2000 beds;doubling in the next years)~ 570 PhDs~ 330 MEuro R&D~ 1250 researchers~ 180 PhDs~ 90 MEuro R&DCross-­‐fer>lize  applied  technology  &  basic  research  
  9. 9. 7Cross-border collaboration: Body Area Network activities in Nl.Join  forces  across  borders  for  a  larger  R&D  market  
  10. 10. Accelerate  the  tech-­‐to-­‐clinical  trial  route  23/05/13 14:50Center for Medical InnovationThe CMI has been created as a non-profit foundation by the Government of Flanders in collaborationwith the universities/university hospitals and the health care industry in Flanders to accelerate thetranslation of innovation in human health care into novel clinical applications. CMI’s first project is thecreation and coordination of the Flemish Biobank, a virtual biobank in specific disease fields, accordingto strict quality criteria for biomaterials and accompanying clinical data sets.The CMI activities contribute in a major way to:Accelerated access to know-how as well as health care products and strategies for the end-user:patient and physician.Better understanding of diseases, their evolution, their treatment and their prevention.The creation of technology platforms that allow for the genesis of new companies with focus onhealth care and med-tech.Smooth transition from academic know-how and understanding to innovation into the R&Dprocess that turns ideas into applications and products.Get to know the CMI !CMI is a member ofWelcome News History Management Contact Members OnlyThe CMI has been created as a non-profit foundation by the Government of Flanders in collaborationwith the universities/university hospitals and the health care industry in Flanders to accelerate thetranslation of innovation in human health care into novel clinical applications. CMI’s first project is thecreation and coordination of the Flemish Biobank, a virtual biobank in specific disease fields, accordingto strict quality criteria for biomaterials and accompanying clinical data sets.The CMI activities contribute in a major way to:Accelerated access to know-how as well as health care products and strategies for the end-user:patient and physician.Better understanding of diseases, their evolution, their treatment and their prevention.The creation of technology platforms that allow for the genesis of new companies with focus onWelcome News History Management Contact Members OnlyCMI  –  Center  for  Medical  Innova>on  
  11. 11. Fund  beyond  novelty  -­‐  Fund  the  gaps  •  Feasibility  &  innova>on  grants  for  SME  •  Grants  for  new  markets  &  products  •  Applied  biomedical  research  (TBM)  •  Transforma>onal  medical  research  (TGO)  •  Feasibility  &  innova>on  grants  for  SME  
  12. 12. 2Short description of the case & Key-Players:• Nanotechnology for Health (NfH): an emerging and promising field;• Mature players looking for further differentiationadopting nanotechnologyallowing to interact at a sub-cellular level and start-ups, especially active as nanotechnologyproviders.• A strong installed basis in the area of bio-pharma and biotech companies (>300 companies in B)• Flanders has a 3 strong major complementary pillars (knowledge base):- Imec (among the largest nano-electronics independent R&D centers world wide diversifyinginto nano-electronics for health- University Hospital Leuven being the largest clinical setting in Europe- VIB: a internationallyrecognized large instituteof biotechnology• NfH case focusing on cluster approach & strategic alliances,both in Flanders andcross-border!Explore  capability  &  capacity  5Eco-system for NfH & innovation chain integrationAcademia &Research CentersIndustry• Selection of FlemishUniversities & R&D centers•Selection of Dutchuniversities• e.g. Promising case ofBiocartis (diagnostics)- Most innovative company of 2011 inmedical segment by World EconomicForum 2011- Raised 71 MEuro in current climateBringing together top-excellenceIn nanotech related healthFocusStrengthening position byadopting nanotechnologies &creating interacting eco-systemof nanotech providers & adoptersCross-border smart specialist regionFocus  on  cluster  approach  &  strategic  alliances,  both  in  Flanders  and  cross-­‐border  Nano  for  Health  -­‐  NfH  -­‐  
  13. 13. Health Axis EuropeMatching Cluster Profiles6Cambridge Leuven HeidelbergInternationally outstanding universities withexcellent health sciences and astrong tradition in top education and researchSubstantial health industry baseDriven by strong key individualswho are personally committed to fostereconomic growth and entrepreneurshipFocused on complementary health technology areasRegenerative medicineand stem cellsMedical electronicsand nanotechnologyPersonalized medicineand cancer researchUpscale  the  impact  KIC  HEALTH  
  14. 14. 2002:  spin-­‐off  VIB+VUB,  2MEuro  seed  2013:  31MEuro  capital  raise  2006:  spin-­‐off  Ugent+IMEC    Bring  to  market  through  several  routes  
  15. 15. •  create  &  enable  top  players  in  their  respec>ve  field  •  focus  •  re-­‐invest  for  strategic  steps  •  create  interac>on  opportuni>es  across  stakeholders  •  build  structural  alliances  for  las>ng  impact  •  co-­‐develop  an  eco-­‐system  with  industry  •  facilitate  abundant  interac>on  opportuni>es  •  ensure  KPIs  along  the  innova>on  chain    Achieving  tangible  results  
  16. 16. Thank  you  imec  Contact:    Dr.  Wolfgang  Eberle  Manager  Public  Funding  Life  Science  Technologies  Coordinator  ERC  grants    imec  Public  R&D  Policies  &  Programs    wolfgang.eberle@imec.be        
  17. 17. Workshop  Nanotech  for  Health  in  Flanders  Thursday,  June  20,  2013  (16:00h  -­‐  18:00h)    This  workshop  will  present  the  final  results  of  the  study  “Nanotech  for  Health”  -­‐  conducted  by  ECOOM  and  imec.  Furthermore  the  cluster  organiza>ons  DSP  Valley  and  FlandersBio  will  provide  more  informa>on  on  how  these  results  will  be  used  to  foster  new  R&D  collabora>ons  between  bio-­‐and  nanotechnology  research  centers  and  the  industry  and  other  stakeholders  involved.  http://www.cmi-vzw.be/Accelerated access to know-how as well as health care products and strategies forpatient and physician.Better understanding of diseases, their evolution, their treatment and their preventioThe creation of technology platforms that allow for the genesis of new companies whealth care and med-tech.Smooth transition from academic know-how and understanding to innovation inprocess that turns ideas into applications and products.Get to know the CMI !CMI is a member ofLeuven.Inc  Visionary  seminar:  ‘The  power  of  converging  technologies  for  tomorrow’s  healthcare’  Date:  Thursday  6  June  2013  LocaUon:  imec,  auditorium,  Kapeldreef  75,  3001  Leuven  (Heverlee)      Nanotech  plaVorms  for  healthcare  Peter  Peumans,  Department  Director  Bio-­‐  and  Nanoelectronics  imec    The  New  Age  of  TranslaUonal  Medicine:  Nanotech  meets  Biotech  Magali  Haas,  CSO  One  Mind  for  Research      Trends  towards  smart  specializaUon    Koen  Debackere,  Managing  Director  KU  Leuven  Research  &  Development  Nanotech  for  health  approach  for  Flanders  Marc  Van  Rossum,  Senior  Strategic  Advisor  for  Nanoelectronics    The  Dual  Core  Program  approach:  a  new  concept  of  open  innovaUon  in  the  life  science  community  Johan  Van  Hellepuke,  Senior  Vice  President  Strategic  Development,  imec  Upcoming  events  

×